---
ver: rpa2
title: Explainable artificial intelligence model predicting the risk of all-cause
  mortality in patients with type 2 diabetes mellitus
arxiv_id: '2507.23491'
source_url: https://arxiv.org/abs/2507.23491
tags:
- mortality
- risk
- diabetes
- patients
- type
- transformers
- self-attention
- retrieval-augmented-generation
- instruction-tuning
- parameter-efficient-finetuning
- mixture-of-experts
- chain-of-thought
core_contribution: This study developed and validated an explainable artificial intelligence
  model for predicting 16.8-year all-cause mortality risk in patients with type 2
  diabetes mellitus. The extra survival trees (EST) model, incorporating ten key clinical
  and laboratory features, achieved strong predictive performance with a C-statistic
  of 0.776 and time-dependent AUC values of 0.86, 0.80, 0.841, and 0.826 for 5-, 10-,
  15-, and 16.8-year mortality predictions respectively.
---

# Explainable artificial intelligence model predicting the risk of all-cause mortality in patients with type 2 diabetes mellitus

## Quick Facts
- arXiv ID: 2507.23491
- Source URL: https://arxiv.org/abs/2507.23491
- Reference count: 40
- Extra Survival Trees model achieved C-statistic of 0.776 and time-dependent AUC values of 0.86, 0.80, 0.841, and 0.826 for 5-, 10-, 15-, and 16.8-year mortality predictions respectively

## Executive Summary
This study developed and validated an explainable artificial intelligence model for predicting 16.8-year all-cause mortality risk in patients with type 2 diabetes mellitus. The extra survival trees (EST) model, incorporating ten key clinical and laboratory features, achieved strong predictive performance with a C-statistic of 0.776 and time-dependent AUC values of 0.86, 0.80, 0.841, and 0.826 for 5-, 10-, 15-, and 16.8-year mortality predictions respectively. Shapley additive explanations (SHAP) analysis provided interpretable insights into individual patient risk predictions, demonstrating the model's potential as a clinical decision-support tool for identifying high-risk patients and optimizing treatment strategies.

## Method Summary
The study used a retrospective cohort of 554 T2DM patients from the Casale Monferrato Study, with 10-fold cross-validation and 80/20 train-test split. The EST model was trained on 123 baseline features (demographics, biomarkers, complications) reduced to 10 through intersection of four feature selection methods. Hyperparameters were optimized using Tree-structured Parzen Estimator (TPE). Model performance was evaluated using C-statistic, time-dependent AUC, and SHAP analysis for interpretability. The final model incorporated age, diabetes complications, NT-proBNP, creatinine, hs-CRP, Apolipoprotein A1, HbA1c, estimated glomerular filtration rate, N-glycan NA3F, and insulin resistance.

## Key Results
- EST model achieved C-statistic of 0.776 for 16.8-year mortality prediction
- Time-dependent AUC values: 0.86 (5 years), 0.80 (10 years), 0.841 (15 years), 0.826 (16.8 years)
- Ten features selected through intersection of four methods, with age, complications, and biomarkers showing strongest associations
- SHAP analysis revealed age and complications as primary risk factors, while Apolipoprotein A1 showed inverse relationship with mortality risk

## Why This Works (Mechanism)

### Mechanism 1
- **Claim:** The Extra Survival Trees (EST) model captures non-linear risk dependencies that traditional linear models (like Cox regression) may miss.
- **Mechanism:** EST utilizes an ensemble of randomized decision trees trained on survival data. By splitting feature space based on random cut-points and aggregating results, it models complex interactions between clinical variables (e.g., how age interacts with creatinine levels) without imposing a proportional hazards assumption.
- **Core assumption:** The relationship between the predictors and the log-hazard of mortality is non-linear and involves interactions that a linear sum of coefficients cannot approximate.
- **Evidence anchors:**
  - [Abstract]: Mentions the EST model achieved strong predictive performance (C-statistic 0.776).
  - [Introduction]: Notes that ML algorithms "offer distinct advantages by capturing non-linear risk function dependencies that Cox regression cannot accommodate."
  - [Corpus]: Neighbor papers (e.g., "Feature-Enhanced Machine Learning...") corroborate the general shift toward ML for handling complex healthcare data over traditional statistical methods.
- **Break condition:** If the true underlying biological risk is strictly additive and linear, the variance introduced by the randomization in EST could result in lower performance compared to a penalized Cox model.

### Mechanism 2
- **Claim:** The model predicts mortality by acting as a multi-system proxy for biological aging and organ-specific dysfunction.
- **Mechanism:** The selected features (e.g., NT-proBNP, creatinine, hs-CRP) are not merely random clinical metrics; the paper argues they represent distinct biological axes: cardiac stress, renal aging, and residual inflammatory risk. The model aggregates these "organ-specific ageotypes" into a composite risk score.
- **Core assumption:** These ten specific biomarkers are sufficient surrogates for the complex, unmeasured processes of biological aging and treatment adherence in T2DM patients.
- **Evidence anchors:**
  - [Results]: "The model seems to capture broader dimensions of biological aging... integrating emerging concepts such as residual inflammatory risk (RIR) and organ-specific ageotyping."
  - [Conclusions]: Links elevated hs-CRP to "residual inflammatory risk" and NT-proBNP to "cardiac aging."
  - [Corpus]: Weak direct support; corpus papers focus on imaging/EHR data rather than these specific serum biomarkers.
- **Break condition:** If a patient has a significant comorbidity or risk factor not represented by these proxies (e.g., severe frailty or undetected cancer), the model will underestimate risk.

### Mechanism 3
- **Claim:** SHAP (Shapley Additive Explanations) transforms the "black box" EST model into a clinical decision-support tool by quantifying individual feature contributions.
- **Mechanism:** SHAP calculates the marginal contribution of each feature to the deviation from the average prediction. It decomposes a patient's risk score into additive parts (e.g., +15% risk from Age, -5% protection from Apolipoprotein A1), making the model locally interpretable.
- **Core assumption:** Clinical validity implies that the magnitude and direction of SHAP values align with known physiological pathways (e.g., high Apolipoprotein A1 being protective).
- **Evidence anchors:**
  - [Abstract]: "SHAP approach was employed to interpret the model's individual decision-making processes."
  - [Results]: "Apolipoprotein A1 showed an inverse relationship... The remaining nine features demonstrate positive associations."
  - [Corpus]: Neighbor "Modeling Day-Long ECG..." uses Explainable AI, validating the trend toward interpretability in mortality prediction.
- **Break condition:** If features are highly collinear (e.g., two features acting as perfect proxies for the same biological process), SHAP values may be unstable or distribute importance arbitrarily between them.

## Foundational Learning

- **Concept: Censored Data in Survival Analysis**
  - **Why needed here:** The dataset includes patients who are still alive (censored). You cannot treat them as "survivors" indefinitely; standard regression would bias the results by ignoring their survival time.
  - **Quick check question:** Why can't we simply train a binary classifier (Dead/Alive) ignoring the time component for patients who are still alive at the end of the study?

- **Concept: Tree-structured Parzen Estimator (TPE)**
  - **Why needed here:** The paper uses TPE for hyperparameter tuning. Understanding this helps explain how they optimized the EST model (e.g., determining tree depth or number of estimators) efficiently.
  - **Quick check question:** How does TPE differ from a standard grid search when optimizing hyperparameters for a model with continuous and categorical parameters?

- **Concept: Mean Absolute SHAP Values**
  - **Why needed here:** The paper ranks features (Age > Complications > Biomarkers) using this metric. It represents the average magnitude of a feature's impact across the entire cohort, regardless of direction.
  - **Quick check question:** If a feature doubles risk for half the patients and halves risk for the other half, would it have a high mean absolute SHAP value?

## Architecture Onboarding

- **Component map:** 554 patients (80% Train / 20% Test split) -> Z-normalization -> KNN Imputation (k=5) -> Feature Selection (Intersection of MI, ReliefF, mRMR, Cox) -> Extra Survival Trees (EST) -> SHAP Kernel/Tree explainer -> 16.8-year mortality probability + Local SHAP waterfall plot

- **Critical path:** The **Feature Selection** intersection step is the primary bottleneck. It aggressively filters features based on four distinct criteria. If a key predictor is missed by just one method, it is dropped from the final model.

- **Design tradeoffs:**
  - **Accuracy vs. Stability:** The model was optimized for the maximum 16.8-year horizon, resulting in "reduced reliability for short-term forecasts" (<5 years) as seen in the time-dependent AUC dip.
  - **Interpretability vs. Complexity:** The authors chose a final set of 10 features (down from 19 candidates) likely to balance model parsimony (easier clinical adoption) with raw predictive power.

- **Failure signatures:**
  - **Short-term Error:** High-risk patients who die within 5 years may be under-predicted because the model weights long-term survival factors (like N-glycan structure) over acute ones.
  - **Unexplained Outcomes:** The paper explicitly notes cases where the model overestimates risk (Fig 3C) or underestimates it (Fig 3D), often due to unmeasured "changes in treatment adherence" or "development of new complications."

- **First 3 experiments:**
  1. **Sanity Check:** Train a standard Cox Proportional Hazards model on the same 10 features and compare the C-index against the EST model to quantify the "non-linear advantage."
  2. **Ablation Study:** Remove the N-glycan NA3F feature (the most novel/unusual variable) and re-evaluate the C-index to determine its specific contribution to performance.
  3. **External Validation:** Apply the trained model to a different T2DM cohort (even if smaller) to test if the specific SHAP thresholds (e.g., NT-proBNP > 100 ng/L) generalize or if the model is overfit to the Italian ancestry of the training set.

## Open Questions the Paper Calls Out
None

## Limitations
- Limited generalizability beyond the Italian T2DM population
- Potential overfitting given the relatively small sample size (n=554)
- Unmeasured confounders affecting long-term mortality predictions
- The model's reduced reliability for short-term forecasts (<5 years)

## Confidence
- **High confidence** in short-term predictive validity (5-year AUC of 0.86)
- **Medium confidence** in long-term 16.8-year predictions and SHAP interpretability
- **Medium confidence** in clinical decision-support potential requiring external validation

## Next Checks
1. External validation on diverse T2DM populations across different geographic regions
2. Prospective study comparing model-guided interventions against standard care protocols
3. Sensitivity analysis testing model performance when N-glycan feature is removed or altered